{
}
UBS analyst Peter Grom has reiterated a Buy rating for PepsiCo, setting a price target of $175, following the company's acquisition of prebiotic soda brand Poppi for $1.95 billion. This move aligns with PepsiCo's strategy to enhance its health-oriented beverage portfolio amid rising consumer demand for healthier options. Despite recent downgrades from Barclays due to concerns over the Frito-Lay division's performance, PepsiCo's strong gross profit margins and attractive valuation present a compelling entry point for investors.
UBS has reaffirmed its Buy rating on PepsiCo, setting a price target of $175, following the company's acquisition of prebiotic soda brand Poppi for $1.95 billion. This move aims to enhance PepsiCo's portfolio in response to the growing demand for healthier beverage options. Despite some analysts lowering earnings forecasts, investor optimism remains, buoyed by PepsiCo's strong gross margins and attractive valuation compared to peers.
UBS has raised its price target for Brown Forman to $39, maintaining a neutral rating, following the company's strong third-quarter results, which exceeded expectations due to favorable one-time effects. Despite a 10% surge in share price, challenges such as subdued growth in the US and uncertainties around tariffs persist, leading to a cautious outlook among investors. Brown Forman's shares are currently trading at attractive valuation levels, yet ongoing market uncertainties may prompt a wait-and-see approach from many.
UBS has increased its price target for Coca-Cola from $72 to $78, maintaining a "Buy" rating following the robust fourth quarter 2024 results. Analyst Peter Grom noted that the beverage manufacturer is expected to have another strong year ahead.
UBS has increased its price target for Coca-Cola from $72 to $78, maintaining a "Buy" rating following robust fourth-quarter 2024 results. Analyst Peter Grom noted that the beverage manufacturer is expected to have another strong year ahead. As of February 12, Coca-Cola's stock was trading at $67.68, reflecting a slight increase of 0.12%.
UBS has lowered its price target for Edgewell Personal Care to $31 from $36 while maintaining a Neutral rating, following a disappointing first-quarter EPS of $0.07, which missed estimates. Despite a 9% drop in stock price, analysts suggest the decline may be an overreaction, given the company's strong fundamentals and potential for future growth, although concerns about top-line visibility persist. Other firms have also adjusted their targets, reflecting challenges from foreign exchange impacts and inconsistent organic growth.
UBS analyst Peter Grom has reaffirmed a Neutral rating on Mondelez International, maintaining a price target of $63.00 ahead of its fourth-quarter EPS report, expected to show earnings of $0.67. Despite a recent stock uptick, investor sentiment is mixed due to concerns over future earnings projections amid rising cocoa prices and foreign exchange fluctuations. The company has also made significant executive changes and announced a strategic partnership with Amazon Web Services, alongside a $9 billion share repurchase program.
UBS analyst Peter Grom has maintained a Neutral rating on Mondelez International (NASDAQ: MDLZ) with a price target of $63.00. The company is scheduled for upcoming developments that may impact its market position.
UBS analyst Peter Grom has maintained a Neutral rating on Clorox stock with a price target of $176, forecasting Q2 EPS at $1.39, slightly below consensus. Despite challenges, sentiment has improved, with five analysts revising earnings estimates upward, indicating potential growth. Clorox reported strong Q1 results, exceeding expectations with a 31% increase in organic sales, while projecting a low-teens sales decrease for Q2 but anticipating 3% to 5% organic growth in the latter half of the year.
UBS analyst Peter Grom has maintained a Neutral rating on Clorox (NYSE: CLX) with a price target of $176.00. The decision reflects the analyst's assessment of the company's current market position and outlook.
Peter Grom
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating for pepsico following poppi acquisition
15:47 18.03.2025
ubs maintains buy rating on pepsico following poppi acquisition
15:47 18.03.2025
ubs raises brown forman price target to 39 dollars amid strong earnings
16:34 07.03.2025
ubs raises coca cola price target to 78 dollars maintains buy rating
08:52 12.02.2025
ubs raises coca cola price target to 78 dollars maintains buy rating
07:52 12.02.2025
ubs lowers edgewell personal care target amid earnings miss and currency challenges
17:11 11.02.2025
ubs maintains neutral rating on mondelez ahead of fourth quarter earnings report
United States Dollar
Mondelez International, Inc.
Amazon.com, Inc.
USA
Volker Kühn
Peter Grom
Brian Stevens
Show more
18:10 28.01.2025
ubs maintains neutral rating and price target for mondelez international
16:27 28.01.2025
ubs maintains neutral rating on clorox with steady price target of 176
17:27 27.01.2025
ubs maintains neutral rating and price target for clorox
16:36 27.01.2025
Trending
Subcategory
Corporate News
Startups & Entrepreneurship
Economic Indicators
Global Trade Developments
Market Analysis and Predictions
Countries:
Companies:
Currencies:
People: